From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

Weight loss is a highly personal journey. Just as there is no one reason for wanting to lose weight, there is also no ...

The terms of the IPO were not disclosed in the filing. Strong equity markets, falling interest rates and hopes of a ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...